On Feb. 26, 2021, Innovation Pharmaceuticals announced that after an interim review, by an independent Data Monitoring Committee (DMC), dosing of Brilacidin was extended to 5 days from the original 3 day regime.

The Phase 2 Brilacidin for COVID-19 clinical trial is a randomized, double-blind, placebo-controlled, international, multi-center study with planned enrollment of ~120 subjects with moderate-to-severe COVID-19.